Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan-based dual vs bismuth quadruple therapy for Helicobacter pylori eradication
ChiCTR2600123942Phase 4Not yet recruiting
- Sponsor
- Shenzhen Nanshan People's Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tegoprazan in Helicobacter pylori infection (3 arms), sponsored by Shenzhen Nanshan People's Hospital. Primary endpoints: Symptom improvement (simplified GSRS score) and H. pylori eradication by 13C-urea breath test. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
tegoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2600123942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123942.